TY - JOUR
T1 - Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma
T2 - the benefits of PCV over TMZ
AU - Rincon-Torroella, Jordina
AU - Rakovec, Maureen
AU - Kalluri, Anita L.
AU - Jiang, Kelly
AU - Weber-Levine, Carly
AU - Parker, Megan
AU - Raj, Divyaansh
AU - Materi, Josh
AU - Sepehri, Sadra
AU - Ferres, Abel
AU - Schreck, Karisa C.
AU - Aldecoa, Iban
AU - Lucas, Calixto Hope G.
AU - Sair, Haris I.
AU - Redmond, Kristin J.
AU - Holdhoff, Matthias
AU - Weingart, Jon
AU - Brem, Henry
AU - Sánchez, Josep J.González
AU - Ye, Xiaobu
AU - Bettegowda, Chetan
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2025/1
Y1 - 2025/1
N2 - Purpose: Oligodendroglioma is an adult-type diffuse glioma defined by 1p/19q codeletion and IDH1/2 mutation. Treatment includes surgery followed by observation alone in select low-grade tumors, or combination radiation and chemotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ). While prospective studies investigating treatments for molecularly defined oligodendrogliomas are ongoing, this retrospective study analyzes the relationship between adjuvant regimens and progression-free survival (PFS). Methods: Adults with IDH-mutant, 1p/19q codeleted oligodendroglioma (WHO grade 2 or 3) who underwent surgery between 2005 and 2021 were identified. Clinical data, disease characteristics, treatment, and outcomes were collected. Results: A total of 207 patients with grade 2 and 70 with grade 3 oligodendrogliomas were identified. Median (IQR) follow-up was 57 (87) months. Patients with grade 3 tumors who received adjuvant radiation and PCV had longer median PFS (> 110 months) than patients who received radiation and TMZ (52 months, p = 0.008) or no adjuvant chemoradiation (83 months, p = 0.03), which was not seen in grade 2 tumors (p = 0.8). In multivariate analysis, patients who received PCV chemotherapy (Relative Risk [95% CI] = 0.24[0.05—1.08] and radiotherapy (0.46[0.21—1.02]) trended towards longer PFS, independently of grade. Conclusion: Adjuvant radiation and PCV are associated with improved PFS over radiation with TMZ in patients with grade 3 molecularly defined oligodendrogliomas, and all-grade patients treated with PCV trended towards decreased risk of recurrence and progression. These results highlight the importance of ongoing clinical trials investigating these treatments.
AB - Purpose: Oligodendroglioma is an adult-type diffuse glioma defined by 1p/19q codeletion and IDH1/2 mutation. Treatment includes surgery followed by observation alone in select low-grade tumors, or combination radiation and chemotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ). While prospective studies investigating treatments for molecularly defined oligodendrogliomas are ongoing, this retrospective study analyzes the relationship between adjuvant regimens and progression-free survival (PFS). Methods: Adults with IDH-mutant, 1p/19q codeleted oligodendroglioma (WHO grade 2 or 3) who underwent surgery between 2005 and 2021 were identified. Clinical data, disease characteristics, treatment, and outcomes were collected. Results: A total of 207 patients with grade 2 and 70 with grade 3 oligodendrogliomas were identified. Median (IQR) follow-up was 57 (87) months. Patients with grade 3 tumors who received adjuvant radiation and PCV had longer median PFS (> 110 months) than patients who received radiation and TMZ (52 months, p = 0.008) or no adjuvant chemoradiation (83 months, p = 0.03), which was not seen in grade 2 tumors (p = 0.8). In multivariate analysis, patients who received PCV chemotherapy (Relative Risk [95% CI] = 0.24[0.05—1.08] and radiotherapy (0.46[0.21—1.02]) trended towards longer PFS, independently of grade. Conclusion: Adjuvant radiation and PCV are associated with improved PFS over radiation with TMZ in patients with grade 3 molecularly defined oligodendrogliomas, and all-grade patients treated with PCV trended towards decreased risk of recurrence and progression. These results highlight the importance of ongoing clinical trials investigating these treatments.
KW - 1p/19q codeletion
KW - IDH mutant
KW - Molecular oligodendroglioma
KW - PCV
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=85205846771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205846771&partnerID=8YFLogxK
U2 - 10.1007/s11060-024-04829-6
DO - 10.1007/s11060-024-04829-6
M3 - Article
C2 - 39382617
AN - SCOPUS:85205846771
SN - 0167-594X
VL - 171
SP - 35
EP - 45
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 1
ER -